↓ Skip to main content

Dove Medical Press

Lung cancer in Brazil: epidemiology and treatment challenges

Overview of attention for article published in Lung Cancer: Targets and Therapy, November 2016
Altmetric Badge

Mentioned by

twitter
1 X user

Readers on

mendeley
120 Mendeley
Title
Lung cancer in Brazil: epidemiology and treatment challenges
Published in
Lung Cancer: Targets and Therapy, November 2016
DOI 10.2147/lctt.s93604
Pubmed ID
Authors

Vanessa Karen de Sá, Juliano C Coelho, Vera Luiza Capelozzi, Sergio Jobim de Azevedo

Abstract

Lung cancer persists throughout the world as a major cause of death. In 2014, data from the Brazilian National Cancer Institute (INCA) estimated 16.400 new cases of lung cancer among men (second most common) and 10.930 new cases among women (fourth most common). These data are consistent for all Brazilian regions and reflect the trends of cancer in the country over the last decade. Brazil is a continental country, the largest in Latin America and fifth in the world, with an estimated population of >200 million. Although the discrepancy in the national income between rich and poor has diminished in the last 2 decades, it is still huge. More than 75% of the Brazilian population do not have private health insurance and rely on the national health care system, where differences in standard of cancer care are evident. It is possible to point out differences from the recommendations of international guidelines in every step of the lung cancer care, from the diagnosis to the treatment of advanced disease. This review aims to describe and recognize these differences as a way to offer a real discussion for future modifications and action points toward delivery of better oncology care in our country.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 120 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 1 <1%
Unknown 119 99%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 25 21%
Researcher 16 13%
Student > Postgraduate 10 8%
Student > Master 9 8%
Student > Doctoral Student 8 7%
Other 20 17%
Unknown 32 27%
Readers by discipline Count As %
Medicine and Dentistry 40 33%
Pharmacology, Toxicology and Pharmaceutical Science 8 7%
Nursing and Health Professions 8 7%
Agricultural and Biological Sciences 6 5%
Biochemistry, Genetics and Molecular Biology 5 4%
Other 12 10%
Unknown 41 34%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 November 2016.
All research outputs
#17,286,379
of 25,374,917 outputs
Outputs from Lung Cancer: Targets and Therapy
#81
of 128 outputs
Outputs of similar age
#205,216
of 317,812 outputs
Outputs of similar age from Lung Cancer: Targets and Therapy
#3
of 4 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 128 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 317,812 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one.